Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer

SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines

“…The occurrence of COVID-19 after the booster dose in a sizeable proportion of cancer patients on active therapy requires attention, and needs to be further explored in large series investigated by international consortia. Nevertheless, the usefulness of a third vaccine dose in cancer patients seems to remain unquestionable at present ( 20 , 21 , 22 , 23 , 24 ), also due to the observed increase of neutralizing antibodies to the Omicron variant ( 10 , 11 , 12 ), and to the generally mild clinical course of SARS-CoV-2 infection we observed, complying with the aim of vaccination to reduce COVID-19-related hospitalizations and deaths. Consistently, the booster dose was reported to significantly associate with lower rates of symptomatic infections in healthy subjects compared to those who received only two vaccine doses ( 13 ).…”

Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study

“…Shapiro et al have confirmed the reinforcement of anti-COVID-19 immunity among the total 88 patients with cancer enrolled, with a statistically significant seroconverting anti-S IgG levels after booster vaccination (p = 0.000062) [18]. Debie and colleagues have reported that the booster induced significantly higher anti-receptorbinding domain (RBD) IgG levels 28 days post-third dose than 28 days post-second dose in 141 cancer patients [19]. Finally, the data from a large cohort of patients with hemato-oncological tumors have confirmed the increased humoral response after the third dose of BNT162b2 SARS-CoV-2 vaccine [20].…”

“…The strength of our data consists in the simultaneous detection of both humoral and cellular immune response. One limit is the low numerosity (N = 142), even though this cohort of the patients with cancer is one of the largest available at the moment [17,18,19,20,27]. Another limit is the lack of a control group that enables us to extend our conclusions in a definitive way.…”

Clinical and Laboratory Features in the Israeli Population with COVID-19 Infection after Pfizer-BioNTech mRNA Booster Vaccination

“…Patients with active cancer have a reduced humoral immune response and an increased risk of severe COVID-19 even after a double dose of BNT162b2 vaccination [ 24 ]. Nevertheless, the third dose of BNT162b2 can induce higher anti-SARS CoV-2 IgG titers than two doses in patients with active malignancy and immunosuppression [ 25 ].…”